MetaVia Inc.
NASDAQ: MTVA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hyung Heon Kim
- Employees
- 9
- Headquarters
- Cambridge, United States
- IPO year
- 2016
- Market cap
- $3.4M
- Website
- https://www.metaviatx.com
Loading MTVA…
Loading profile data…Frequently asked questions about MTVA
What does MetaVia Inc. (MTVA) do?
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a...
Where does MTVA trade?
MetaVia Inc. (MTVA) trades on the NASDAQ Global Market.
What sector is MTVA in?
MetaVia Inc. (MTVA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MetaVia Inc.?
Hyung Heon Kim is the chief executive officer of MetaVia Inc. (MTVA).
Where is MetaVia Inc. headquartered?
MetaVia Inc. is headquartered in United States.
Does MTVA pay a dividend?
MetaVia Inc. (MTVA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MTVA go public?
MetaVia Inc. (MTVA) completed its initial public offering in 2016.